Preclinical investigations and early-phase clinical trials have yielded promising results about the effectiveness of HDACis in treating melanoma; some research shows that HDACis can effectively decrease the growth of melanoma, cause tumors to shrink, and amplify the therapeutic benefits of other treatments like BRAF and MEK inhibitors [70]. This evidence concerns the gene MAP2K7 and melanoma.